1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) Program - National Institute on Drug Abuse (NIDA) is sponsored by National Institute on Drug Abuse (NIDA). NIDA leverages the SBIR program to bridge the gap between addiction science breakthroughs and real-world implementation by supporting high-risk, high-impact innovations. This includes digital health tools and AI/ML technologies to prevent, diagnose, and treat substance use disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Innovation Research (SBIR) and Technology Transfer (STTR) Programs | National Institute on Drug Abuse (NIDA) Small Business Innovation Research (SBIR) and Technology Transfer (STTR) Programs Each year, NIDA provides more than $50 million in awards to small businesses through the Small Business programs. That’s up to $3. 4 million in funding per project and all equity remains with grantees.
NIDA invites aspiring entrepreneurs, startups, and small businesses to explore this section and begin the application process.
View the Landscape of Pharmacotherapeutic Development View the Landscape of Medical Device Development Get Started with the Application Process Access a suite of resources to successfully submit a grant application Additional resources for companies Review a complete collection of small business grants previously awarded by NIDA Access current small business opportunities from NIDA SBIR/STTR Success Stories The following companies have received NIDA funding through the SBIR and STTR programs Target Product Profiles (TPPs) for Medical Product Development Before applying, potential applicants are strongly encouraged to discuss their research proposals
According to the current listing, eligibility includes: For-profit small businesses (fewer than 500 employees), independently owned and operated, with a majority ownership by U.S. citizens or permanent resident aliens. Confirm the full requirements in the official notice before applying.
The current listing shows up to $2,000,000 (Phase I up to $275,000; Phase II up to $1.8 million). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Innovation Research (SBIR) Program - National Institute on Drug Abuse (NIDA) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article